- |||||||||| carfilzomib / Generic mfg., Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 19, 2018 P1/2, N=8, Terminated, N=13 --> 0 | Recruiting --> Withdrawn Trial completion date: Apr 2019 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2019 --> May 2018; slow accrual
- |||||||||| Phase classification, Trial completion date, Trial termination, Metastases: Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer (clinicaltrials.gov) - Nov 7, 2018
P=N/A, N=11, Terminated, Completed --> Terminated Phase classification: P2 --> P=N/A | Trial completion date: Aug 2017 --> Apr 2017 | Active, not recruiting --> Terminated; PI left the department; protocol transfer did not take place.
- |||||||||| cyclophosphamide / Generic mfg.
Trial completion, Phase classification, Trial completion date, Trial primary completion date, Post-transplantation: Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (clinicaltrials.gov) - Oct 17, 2018 P1, N=127, Completed, Recruiting --> Completed | Trial completion date: Jun 2017 --> Oct 2018 | Trial primary completion date: Dec 2016 --> Jun 2018 Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2022 --> Mar 2018 | Trial primary completion date: Jun 2019 --> Mar 2018
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma (clinicaltrials.gov) - Oct 17, 2018 P1, N=6, Terminated, Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2022 --> Mar 2018 | Trial primary completion date: Jun 2019 --> Mar 2018 N=25 --> 6 | Trial completion date: Jun 2019 --> Jul 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Jul 2017; Low accrual
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial termination, Trial primary completion date: BIBLOS: Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (clinicaltrials.gov) - Oct 11, 2018 P1, N=85, Terminated, Phase classification: P2 --> P1 Trial completion date: Nov 2019 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Dec 2017; ANSM decision due to veino occlusive disease (security alert)
- |||||||||| buparlisib (AN2025) / Novartis, Adlai Nortye
Phase classification: Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 10, 2018 P1, N=7, Completed, Trial completion date: Nov 2019 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2018 --> Dec 2017; ANSM decision due to veino occlusive disease (security alert) Phase classification: P=N/A --> P1
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date, Pre-transplantation, Post-transplantation: Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Sep 21, 2018 P1/2, N=67, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2018 | Trial primary completion date: Jan 2020 --> Jul 2018 Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Nov 2018
- |||||||||| alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Enrollment closed, Enrollment change, Trial primary completion date: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Sep 19, 2018 P1, N=42, Active, not recruiting, Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Nov 2018 Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018
- |||||||||| Trial completion, Phase classification: 124I-FIAU Imaging in EBV and KSHV Associated Cancers (clinicaltrials.gov) - Sep 17, 2018
P=N/A, N=12, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P1 --> PN/A
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Cardiac Fibrosis by CMR in Patients With Cancer (clinicaltrials.gov) - Sep 14, 2018 P=N/A, N=0, Withdrawn, Recruiting --> Completed | Phase classification: P1 --> PN/A N=12 --> 0 | Trial completion date: Feb 2019 --> Aug 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2019 --> Aug 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Genetic Study of Families With High Frequency of Hodgkin Lymphoma (clinicaltrials.gov) - Sep 12, 2018
P=N/A, N=27, Completed, Phase classification: P1/2 --> P1 | Trial primary completion date: Jul 2018 --> Apr 2017 Recruiting --> Completed | N=50 --> 27 | Trial completion date: Jul 2019 --> Feb 2018 | Trial primary completion date: Jul 2019 --> Feb 2018
- |||||||||| Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (clinicaltrials.gov) - Sep 10, 2018 P1, N=20, Completed, Trial primary completion date: Jan 2100 --> Oct 2018 N=15 --> 20 | Trial completion date: Jun 2018 --> Jul 2016 | Trial primary completion date: Apr 2018 --> Apr 2016 | Active, not recruiting --> Completed
- |||||||||| dexamethasone / Generic mfg., carboplatin / Generic mfg., bendamustine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma (clinicaltrials.gov) - Sep 6, 2018 P2, N=30, Completed, Trial primary completion date: Jun 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Sep 2017 | Trial primary completion date: Jul 2018 --> Sep 2017
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion, Trial completion date: BRAN: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas (clinicaltrials.gov) - Sep 6, 2018 P2, N=33, Completed, Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Sep 2017 | Trial primary completion date: Jul 2018 --> Sep 2017 Recruiting --> Completed | Trial completion date: Dec 2018 --> Sep 2018
- |||||||||| cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Aug 31, 2018 P2, N=142, Completed, N=40 --> 16 | Completed --> Terminated; slow accrual/lack of resources/low priority due to combining 2 consortia Active, not recruiting --> Completed | N=92 --> 142
|